Abstract
PURPOSE: The role of immunoscintigraphy with111 Insatumomab pendetide in the medical and/or surgical management of colorectal cancer patients was evaluated in a multicenter trial. METHODS: This 103 patient study population included 46 individuals with rising serum carcinoembryonic antigen levels and otherwise negative diagnostic evaluation, 29 patients with known recurrence, presumed to be isolated and resectable, and 28 patients for whom standard diagnostic tests provided equivocal information. RESULTS: No adverse reactions were noted following intravenous administration of 1 mg of satumomab pendetide radiolabeled with approximately 5 mCi of111 In. Thirty percent of patients developed human anti-mouse antibodies postinfusion. In the 84 patients for whom correlation with histopathologic, diagnostic, and/or clinical findings was available, antibody imaging demonstrated a sensitivity of 73 percent in patients with confirmed tumor (36/49) and negative results for all 35 patients with no evidence of malignancy. Occult disease was detected in 18 patients. CONCLUSION: 111 In-satumomab pendetide immunoscintigraphy was helpful in the medical and/or surgical management of 45 (44 percent) patients and provided information unavailable from other diagnostic modalities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Collier BD, Abdel-Nabi H, Doerr RJ,et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179–86.
Goldenberg DM, Goldenberg H, Sharkey RM,et al. Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 1989;19:262–81.
Rodwell JD, Alvarez VL, Lee C,et al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986;83:2632–6.
Perkins AC, Pimm MV. Role of animal models for the pre-clinical evaluation of antibody preparations. Immunoscintigraphy: practical aspects and clinical applications. New York: John Wiley & Sons 1991: 39–55.
Harwood SJ, Carroll RG, Webster WB,et al. Human biodistribution of111 In-labeled B72.3 monoclonal antibody. Cancer Res 1990;50(Suppl):932s-6s.
Galandiuk S, Wieand HS, Moertel CG,et al. Patterns of recurrence after curative resection of carcinomas of the colon and rectum. Surg Gynecol Obstet 1992;174:27–32.
Winzelberg GG, Grossman SJ, Rizk S,et al. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Cancer 1992;69:1656–63.
Moss AA. Imaging of colorectal carcinoma. Radiology 1989;170:308–10.
Petersen BM Jr, Bass BL, Bates HR, Chandeysson PL, Harmon JW. Use of the radiolabeled murine monoclonal antibody,111 In-CYT-103, in the management of colon cancer. Am J Surg 1993;165:137–43.
Author information
Authors and Affiliations
Additional information
Funded in part by a grant from Cytogen Corporation, Princeton, NJ.
Read at the meeting of The American Society of Colon and Rectal Surgeons, San Francisco, California, June 7 to 12, 1992. Results from one of the investigational sites included in this multicenter trial are reported in Weineret al., Cancer Invest (in press).
About this article
Cite this article
Corman, M.L., Galandiuk, S., Block, G.E. et al. Immunoscintigraphy with111 In-satumomab pendetide in patients with colorectal adenocarcinoma: Performance and impact on clinical management. Dis Colon Rectum 37, 129–137 (1994). https://doi.org/10.1007/BF02047534
Issue Date:
DOI: https://doi.org/10.1007/BF02047534